Zai Lab (ZLAB) EBT Margin (2019 - 2026)

Zai Lab (ZLAB) posted EBT Margin of 49.77% for Q1 2026, down 19.07% sequentially from 41.8% in Q4 2025, and down 428.0% YoY from 15.17% in Q1 2025.

Zai Lab (ZLAB) EBT Margin (2019 - 2026) Analysis & Trends

Zai Lab has reported EBT Margin for 8 years, with the latest figure at 49.77% in Q1 2026.

Quarterly EBT Margin fell 428.0% year-over-year to 49.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.62% (up 2063.0% YoY) and the FY2025 annual result came in at 38.78%, up 2566.0% from the prior year.
EBT Margin declined to 49.77% in Q1 2026 per ZLAB's latest filing, from 41.8% in the prior quarter.
Over five years, EBT Margin peaked at 30.98% in Q3 2025 and troughed at 286.31% in Q2 2022.
A 5-year average of 105.98% and a median of 78.26% in 2023 frame the typical range for EBT Margin.
The widest YoY moves for EBT Margin: up 98368 bps in 2022, down 5725 bps in 2022.
Over 5 years, EBT Margin stood at 98.67% in 2022, then slumped by 47 bps to 144.96% in 2023, then surged by 48 bps to 74.89% in 2024, then surged by 44 bps to 41.8% in 2025, then retreated by 19 bps to 49.77% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 49.77%, 41.8%, and 30.98% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Zai Lab	2.91 Bn	2.20 Bn	58.15 Mn	-48.77%

Download Data